Related Experiment Videos

Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins

Yong Zhang1, Xinsheng Gao, Leslie J Saucedo

  • 1Department of Physiology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, TX 75390-9040, USA.

Nature Cell Biology
|May 29, 2003
PubMed

Insights

Mutations in TSC1 or TSC2 genes cause tuberous sclerosis. This study identifies Rheb (Ras homologue enriched in brain) as a direct target of Tsc2 GTPase-activating protein (GAP) activity, revealing a key molecular mechanism.

Area of Science:

  • Molecular biology
  • Genetics
  • Biochemistry

Background:

  • Tuberous sclerosis is a benign tumor syndrome caused by mutations in TSC1 or TSC2 genes.
  • Tsc2 protein contains a domain homologous to GTPase-activating protein (GAP) domains, suggesting a GTPase as its physiological target.

Purpose of the Study:

  • To identify the direct molecular target of Tsc2's GTPase-activating protein (GAP) activity.
  • To elucidate the role of Rheb (Ras homologue enriched in brain) in the TSC tumor suppressor pathway.

Main Methods:

  • In vivo and in vitro assays were used to investigate the interaction between Tsc2 and Rheb.
  • Site-directed mutagenesis was employed to study the function of the Tsc2 GAP domain.

Main Results:

  • Rheb was identified as a direct target of Tsc2 GAP activity.
  • Mutations in the Tsc2 GAP domain impaired Rheb regulation but not Tsc1 complex formation.

Conclusions:

  • Rheb is a direct molecular target of the TSC tumor suppressor complex.
  • This finding provides a mechanistic link between TSC gene mutations and tumor development.

Related Concept Videos